Detail of "2072-71-1"

Reference

Cysteine analogs potentiate glucose-induced insulin release in vitro

Cysteine analogs potentiate glucose-induced insulin release in vitro. Ammon, H. P. T.; Hehl, K. H.; Enz, G.; Setiadi-Ranti, A.; Verspohl, E. J. (Dep. Pharmacol., Inst. Pharm. Sci., Tuebingen D-7400, Fed. Rep. Ger.). Diabetes, 35(12), 1390-6 (English) 1986. CODEN: DIAEAZ. ISSN: 0012-1797. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 13 In rat pancreatic islets, cysteine analogs, including glutathione [70-18-8], acetylcysteine [616-91-1], cysteamine [60-23-1], D-penicillamine [52-67-5], D-cysteine Et ester [85950-53-4], and cysteine [52-90-4] potentiated glucose [50-99-7]t (11.1 mM)-induced insulin [9004-10-8] secretion in a concn.-dependent manner. Their maximal effects were similar and occurred at ~0.05, 0.05, 0.1, 0.5, 1.0, 1.0 mM, resp. At substimulatory glucose levels (2.8 mM), insulin release was not affected by these compds. In contrast, thiol compds. structurally different from cysteine and its analogs, such as mesna [19767-45-4], tiopronin [1953-02-2], meso-2,3-dimercaptosuccinic acid (DMSA) [304-55-2], dimercaprol (BAL) [59-52-9], b-thio-D-glucose [7534-35-2], as well as those cysteine analogs that lack a free-SH group, including L-cystine [56-89-3], cystamine [51-85-4], D-penicillamine disulfide [20902-45-8], S-carbocysteine [638-23-3], and S-carbamoyl-L-cysteine [2072-71-1], did not enhance insulin release at stimulatory glucose levels (11.1 mM); cystine (5 mM) was inhibitory. These in vitro data indicate that among the thiols tested here, only cysteine and its analogs potentiate glucose-induced insulin secretion, whereas thiols that are structurally not related to cysteine do not. This suggests that a cysteine moiety in the mol. is necessary for the insulinotropic effect. For their synergistic action to glucose, the availability of a sulfhydryl group is also a prerequisite. The maximal synergistic action is similar for all cysteine analogs tested, whereas the potency of action is different, suggesting similarity in the mechanism of action but differences in the affinity to the secretory system.

Study of the antitumoral activity of S-carbamoyl-L-cysteine derivatives in animal experiments

Study of the antitumoral activity of S-carbamoyl-L-cysteine derivatives in animal experiments. Nemeth, L.; Somfai-Relle, S.; Kellner, B.; Sugar, J.; Bognar, R.; Farkas, J.; Balint, J.; Palyi, I.; Toth, K.; et al. (Res. Inst. Oncopathol., Budapest, Hung.). Arzneim.-Forsch., 28(7), 1119-23 (English) 1978. CODEN: ARZNAD. ISSN: 0004-4172. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) The antitumoral activity of S-(ethylcarbamoyl)-L-cysteine (I) [4909-58-4] and S-[(2-chloroethyl)carbamoyl]-L-cysteine [53330-03-3] in 5 mouse and 5 rat tumors was greater than the activity of their parent compd. S-carbamoyl-L-cysteine [2072-71-1]. No significant change in the toxicity of the derivs. was obsd. The possible mechanism of action of I is discussed.